Table 1.

Demographics, Characterization of Episodes and Associated Symptoms

Variable	Value
Demographic characteristics
Age at enrollment, y	30.7 (19.7–69.8)
Female sex, persons, %	66.7
Site of birth or exposure, persons, %
Latin America	61.9
Asia	28.6
Africa	4.8
No foreign exposure	4.8
Expatriates or travelers with >1 mo of exposure in NCC-endemic area, %	14.3
Follow-up duration, y
At NIH only	8.5 (0.3–28)
At NIH and elsewhere	10.6 (0.4–29.2)
Episodes
≥1, persons, no.	21
Total no.	78
Evaluable for symptoms within 1 y of enrollment	65/78 (83.3)
Recurrent	18/21 (85.7)
No./person	3 (0.1–5)
Incidence, no./evaluable year (range)	0.42 (0.1–5)
Any asymptomatic	13/21 (61.9)
1 symptomatic	7/13 (53.8)
2 symptomatic	6/13 (46.2)
Multiple occurrences	15/78 (19.2)
Clinical symptoms of episodes
Symptomatic	46/65 (70.8)
Asymptomatic	19/65 (29.2)
Focal seizures	19/65 (29.2)
Generalized seizures	12/65 (18.5)
Focal neurological	11/65 (16.9)
Focal seizures with generalization	2/65 (3.1)
Headaches	2/65 (3.1)

Data are no. of persons with the characteristic/no. evaluated (%) or median value (range), unless otherwise indicated.

Abbreviations: NCC, neurocysticercosis; NIH, National Institutes of Health.